BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, May 6, 2026
Breaking News: Read BioWorld's AACR 2026 coverageBreaking News: Read BioWorld's AACR 2026 coverageBreaking News: Best of BioWorld: Q1
Home » Topics » BioWorld Science

BioWorld Science
BioWorld Science RSS Feed RSS

Illustration of ovary, uterus and endometrial cancer.
Immuno-oncology

CLDN6-23-ADC shows promise for ovarian, endometrial tumors

Feb. 29, 2024
Claudin-6 (CLDN6) is highly expressed in several cancer types, including ovarian and endometrial cancers, while very low or no expression is found in normal tissues.
Read More
Hands holding holographic intestine
Gastrointestinal

Ladon’s LDN-071 ameliorates severity in experimental colitis

Feb. 29, 2024
The efficacy of anti-inflammatory therapies used for treating inflammatory bowel disease (IBD) is still not optimal.
Read More
Cancer

First gold complex immunotherapeutic approach in liver cancer

Feb. 29, 2024
Hepatocellular carcinoma (HCC) is a complex disease where both the activation of the cyclic GMP-AMP synthase-stimulator of the interferon gene (cGAS-STING) pathway and the induction of immunogenic cell death (ICD) have proven effective immunotherapeutic strategies in some instances.
Read More
Cancer

123I-ATT-001 cleared to enter clinic in UK for glioblastoma

Feb. 29, 2024
Ariceum Therapeutics GmbH has received approval from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) to conduct a phase I trial (CITADEL-123) of 123I-ATT-001, its iodine-123 labeled PARP inhibitor, in patients with recurrent glioblastoma. The study is expected to begin in the U.K. in June of 2024.
Read More
Colorized transmission electron micrograph of rabies virus particles (teal) next to an image of a lone wandering dog.
Immune

Dyadic and Rabian collaborate on rabies prophylactics and vaccines

Feb. 29, 2024
Dyadic International Inc.'s Dutch subsidiary, Dyadic Nederland BV, has entered into a strategic partnership agreement and collaboration with Rabian BV to develop efficacious, scalable, and affordable rabies prophylactics and vaccines utilizing Dyadic's C1 protein production platform.
Read More
Zebra-print ribbon
Biomarkers

Disease-specific biomarkers in mitochondrial β-oxidation disorders

Feb. 29, 2024
Long-chain fatty acid beta-oxidation disorders (lcFAOD) are a group of inherited metabolic diseases, characterized by the accumulation of disease-specific acyl-CoAs reflecting the enzyme deficiency. The exact consequence of accumulating lcFAO-intermediates and their influence on cellular lipid homeostasis in patients with these diseases is unknown.
Read More
Cancer

Kinase inhibitor HI-TOPK-032 enhances cell-based IL-2 therapy

Feb. 29, 2024
Researchers from Capital Medical University have presented preclinical data for the novel PDZ-binding kinase (PBK) inhibitor, HI-TOPK-032, which is being developed for the treatment of cancer. The study aimed to assess the effects of the candidate on NK-92MI cell infiltration into ovarian tumors.
Read More
Epigenetics concept art.
Drug Design, Drug Delivery & Technologies

Zinc finger approach mutes the epigenome to reduce cholesterol

Feb. 29, 2024
By Mar de Miguel
An Italian group of researchers has used zinc finger editing to silence the PCSK9 gene and improve blood cholesterol levels in mice by applying a single dose of their modifier. The epigenetic-based method could be an alternative to genome editing.
Read More
Brush scrubbing brain figurine with soap
Neurology/Psychiatric

Studies bring insights into brain’s self-cleaning mechanisms

Feb. 28, 2024
By Anette Breindl
Separate teams of investigators have reported new insights into how the brain disposes of metabolic waste via the glia-based lymphatic system, or glymph system. In two papers published in Nature on Feb. 28, 2024, scientists from Washington University in St. Louis described how in sleeping animals, the synchronized activity of neurons drove ionic gradients that facilitated the movement of fluid through brain tissue. And researchers from the Massachusetts Institute of Technology showed that, in a mouse model of Alzheimer’s disease (AD), the glymphatic system mediated clearance of amyloid-β after sensory stimulation at a 40-Hertz rhythm.
Read More
Cancer

Hangzhou Zhongmei Huadong Pharmaceutical discovers new GTPase KRAS inhibitors for cancer

Feb. 28, 2024
Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has described GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Read More
Previous 1 2 … 782 783 784 785 786 787 788 789 790 … 18060 18061 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 6, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 5, 2026
  • The epidermal growth factor receptor in the inactive (left) and active (right) form.

    Cytospire raises £61M series A to target EGFR in solid tumors

    BioWorld
    Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
  • Strategy compass

    Bio Korea 2026: US policy risks shift to execution framework

    BioWorld
    Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
  • DNA, dollars illustration

    Latus Bio series A financing supports early-stage programs

    BioWorld Science

    Latus Bio Inc. has closed a $97 million series A financing to support its broad therapeutics pipeline based on novel AAV capsid variants. Proceeds from the...

  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing